Lantheus (LNTH) announces that its PET imaging agent MK-6240 met key study endpoints in Alzheimer's diagnosis; FDA filing ...

Company plans to file NDA in the third quarter of this yearBEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined ...

Most adults in the US would take a blood test to assess whether they will develop Alzheimer's, according to the survey, ...

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET 1 imaging agent, ...

Professor Frédéric Courbon, Head of the Medical Imaging Department - University Cancer Institute of Toulouse – Oncopole, commented, “PSMA-PET imaging is dramatically changing prostate cancer ...

MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent ...

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX ...

Cubresa’s NuPET™ is a revolutionary in-bore PET scanner that inserts into existing MRI instruments to create a powerful and flexible hybrid preclinical in vivo imaging platform that combines ...